New injectable targets double-chin fat
View this email in your browser

FDA approves new submental fat injectable

ASDSA is pleased to report that the FDA today announced approval of Kybella (deoxycholic acid), an injectable treatment for adults with moderate-to-severe submental fat.
Kybella (previously known as ATX-101), manufactured by Kythera Biopharmaceuticals Inc., is administered into the fat tissue in the submental area. The synthetically derived deoxycholic acid destroys the fat, leaving surrounding tissue largely unaffected. The FDA indicated in its announcement that patients can receive up to 50 injections in a single treatment, with up to six single treatments administered no less than one month apart.
ASDSA members have played leading roles in advocating for, creating and testing the new treatment:
  • In March, ASDS/ASDSA President-Elect Naomi Lawrence, MD, testified on behalf of the Association before an FDA advisory committee in support of the new drug application for ATX-101, as submitted by Kythera Biopharmaceuticals. The advisory committee extended its unanimous approval.
  • Personal research conducted by ASDS/ASDSA Board member Adam M. Rotunda, MD, illuminated the active ingredient in the treatment.
  • As part of their practices, several ASDSA members served as principal investigators of the drug during clinical trials.
Results of the 2014 ASDS Consumer Survey on Cosmetic Dermatologic Procedures have been quoted extensively in media stories regarding the drug as 68 percent of respondents indicated they were somewhat to extremely bothered by excess fat under the chin/neck.
Copyright © 2015 American Society for Dermatologic Surgery Association, All rights reserved.

unsubscribe from this list    update subscription preferences